RxDoctor Payments Data

Derek Einhorn, MD

Internal Medicine · Novi, MINPI 1801855762

Payments from drug & device makers

$5,954in general payments, 2019–2025

Across 352 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$884
  • AbbVie$882
  • Novo Nordisk$798
  • Pfizer$508
  • AstraZeneca$298
  • Boehringer Ingelheim$257
  • plus $2K from 42 others

What the payments were for

  • Food & beverage$5,940100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,954 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$70,847
Medicare patients
183
Services billed
3,724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide117$162,903
OzempicSemaglutide62$93,337
JardianceEmpagliflozin38$41,956
EliquisApixaban24$28,407
FarxigaDapagliflozin Propanediol15$16,605
ShingrixVaricella-Zoster Ge/As01b/Pf38$8,388
PaxlovidNirmatrelvir/Ritonavir17$2,859
Atorvastatin Calcium245$2,508
Losartan Potassium149$1,917
Rosuvastatin Calcium100$1,678
Omeprazole107$1,624
Levothyroxine Sodium134$1,250
Boostrix TdapDiphth,pertuss(Acell),tet Vac17$1,168
Pantoprazole Sodium49$1,023
Simvastatin91$1,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$884$162,903117 claims
Novo NordiskOzempic$798$93,33762 claims
Boehringer IngelheimJardiance$257$41,95638 claims
PfizerEliquis, Paxlovid$508$31,26641 claims
AstraZenecaFarxiga$298$16,60515 claims
GSKShingrix$198$8,38838 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Novi

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →